Dianthus Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Dianthus Therapeutics, Inc. (DNTH) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-84.97-43.56-28.48-71.14-74.94-76.77-57.52
Depreciation & Amortization0.410.360.152.021.981.840.88
Stock Based Compensation12.892.901.520.060.000.000.00
Change in Working Capital-0.354.86-1.653.14-1.198.834.17
Change in Accounts Receivable0.180.750.07-1.010.000.000.00
Change in Accounts Payable8.190.662.284.920.000.000.00
Change in Other Working Capital-10.283.50-4.89-0.770.000.000.00
Other Operating Activities-6.174.323.8710.319.948.990.00
Net Cash from Operating Activities-78.18-36.86-29.07-9.90-64.02-57.10-41.89
Investing Activities
Capital Expenditures-0.11-0.11-0.14-0.030.403.06-7.66
Purchases of Investments-286.71-57.42-59.680.000.000.000.00
Sales/Maturities of Investments127.0077.79-59.6844.69-10.244.59-84.04
Net Cash from Investing Activities-286.8120.25-59.82-0.03-10.641.53-91.70
Financing Activities
Debt Repayment0.00-0.380.000.000.000.000.00
Common Stock Issued270.2972.003.0286.5464.9660.87145.30
Other Financing Activities-14.6761.57-3.32-0.090.00-0.60-3.18
Net Cash from Financing Activities255.62133.5796.6814.9167.7462.30142.15
Summary
Net Change in Cash-109.37116.977.794.98-6.926.738.56
Cash at Beginning of Period132.3915.437.642.6666.8560.1351.57
Cash at End of Period23.02132.3915.437.6459.9366.8560.13
Free Cash Flow-78.29-36.97-29.21-9.94-64.42-60.16-49.56